Show simple item record

dc.creatorHussain, Arif
dc.creatorHasan, Anwarul
dc.creatorNejadi Babadaei, Mohammad Mahdi
dc.creatorHaj Bloukh, Samir
dc.creatorChowdhury, Muhammad E.H.
dc.creatorSharifi, Majid
dc.creatorHaghighat, Setareh
dc.creatorFalahati, Mojtaba
dc.date.accessioned2020-08-12T19:27:36Z
dc.date.available2020-08-12T19:27:36Z
dc.date.created2020
dc.identifier.issn0753-3322spa
dc.identifier.otherhttps://doi.org/10.1016/j.biopha.2020.110559spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11887
dc.description.abstractAs the number of people infected with the newly identified 2019 novel coronavirus (SARSCoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARSCoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARSCoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARSCoV2 S-protein RBD. Finally, some ongoing challenges and future perspective for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV.spa
dc.format.extent30 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherBiomedicine & Pharmacotherapyspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCorona virusspa
dc.subjectSpike proteinspa
dc.subjectReceptor binding domainspa
dc.subjectAntibodiesspa
dc.subjectEpitope-specific vaccines (ESV)spa
dc.titleTargeting SARS-CoV2 spike protein receptor binding domain by therapeutic antibodiesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.biopha.2020.110559spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record